Chronic kidney disease (CKD) has no cure, and few treatment options targeted at slowing the decline in glomerular filtration rate (GFR). Several small clinical trials have indicated that oral sodium bicarbonate (NaHCO3) targets and slows the decline in GFR in CKD. The reported beneficial effects of NaHCO3 in this setting have led to its now common use clinically. It’s known however, that chronic alkali ingestion can promote potassium (K+) wasting, and that K+ depletion has been linked with metabolic dysregulation. Further, CKD patients who are supplemented chronically with oral NaHCO3 display significantly decreased plasma K+ levels relative to control treated counterparts, although these decreases in plasma K+ remain within normal range. No study has investigated the metabolic impacts of chronic NaHCO3 treatment and K+ wasting in CKD. To this end, we tested the hypothesis that in the setting of high tubular flow, chronic NaHCO3 ingestion would promote K+ wasting and metabolic dysfunction. In order to test our hypothesis, 9 male, 8 wk old Sprague Dawley (SD) rats underwent a 2/3 nephrectomy (Nx) and telemetry implantation. The 2/3 Nx is a model of reduced renal mass that has increased single nephron GFR in the absence of metabolic acidosis, similar to most human patients with CKD. Following 4 weeks of recovery, animals were given either 0.1M NaHCO3 (Bicarb, n=3), 0.1M NaCl (Vehicle, n=3) or 0.2M NH4Cl‐NaHCO3 (AC/B, n=3) in the drinking water for 12 weeks. Following 9 weeks of drinking water treatment, we observed a significantly higher hemoglobin A1c in our bicarb treated group compared to vehicle and AC/B treated groups (Bicarb 4.6 ± 0.1 vs Veh 4.2 ± 0.3 vs AC/B 4.2 ± 0.2; One‐way ANOVA, p=0.05). Following another 3 weeks of drinking water treatment, we performed blood gas measurements to assess plasma K+. In contrast to our hypothesis we observed the highest levels of plasma K+ in our bicarb treated animals compared to our vehicle or AC/B groups (Bicarb 5.18 ± 0.28 vs Veh 4.48 ± 0.66 vs AC/B 4.5 ± 0.21; One‐way ANOVA, p=0.16). Our data show that oral NaHCO3 could worsen blood glucose control in the setting of high tubular flow. Additionally, plasma K+ may not be a reliable measure for assessment of K+ status in CKD patients supplemented with NaHCO3. As the majority of K+ is stored intracellularly, further studies characterizing the effect of chronic alkali ingestion on total body K+ are warranted to assess the impact of NaHCO3 on K+ depletion in this patient population.Support or Funding InformationNIH PO1H134604 and DK099548
Read full abstract